Want to see GB:OBI full AI Analyst Report?
Top Page
Ondine Biomedical, Inc.
(LSE:OBI)
Select Model
Select Model
Rating:49Neutral
Price Target:
12.50 p
▲(6.38% Upside)
Action:Reiterated
Date:08/24/26
The score is primarily held back by weak financial performance—very large losses, declining gross margin, and worsening cash burn—despite solid revenue growth and low leverage. Technical indicators also point to negative momentum (below key moving averages and negative MACD). Offsetting this, corporate updates are positive around clinical progress and adoption, while valuation remains difficult to assess due to negative earnings and no stated dividend yield.
Positive Factors
Revenue Growth
Strong recent revenue growth indicates improving commercial traction and increasing customer demand. If sustained, a larger revenue base could help absorb fixed costs, support operating leverage, and provide a foundation for the company to scale its antimicrobial technology over the next several quarters.
Negative Factors
Severe Unprofitability
The scale of losses relative to revenue shows that the business has not yet demonstrated sustainable operating economics. Continued heavy investment without meaningful improvement in operating leverage could delay profitability, constrain strategic choices, and require additional capital before growth translates into durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong recent revenue growth indicates improving commercial traction and increasing customer demand. If sustained, a larger revenue base could help absorb fixed costs, support operating leverage, and provide a foundation for the company to scale its antimicrobial technology over the next several quarters.
Read all positive factors
Ondine Biomedical, Inc. (OBI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£58.32M
Dividend YieldN/A
Average Volume (3M)595.44K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue Growth22.87%
EPS Growth13.35%
CountryUK
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding518,366,940
10 Day Avg. Volume1,146,586
30 Day Avg. Volume595,436
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)21.53
Price to Sales (P/S)28.32
P/FCF Ratio-3.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£12.20M
Ondine Biomedical, Inc. Business Overview & Revenue Model
Company Description
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is P...
How the Company Makes Money
Publicly available, specific details of Ondine Biomedical, Inc.’s (OBI’s) current revenue model, key revenue streams (e.g., product sales, licensing/royalties, services), and material commercial partnerships are null. At a high level, companies co...
Ondine Biomedical, Inc. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.65M | 2.05M | 1.20M | 638.00K | 2.57M |
| Gross Profit | 1.09M | 1.32M | 703.00K | 287.00K | 1.25M |
| EBITDA | -29.45M | -18.49M | -13.79M | -18.85M | -48.36M |
| Net Income | -29.59M | -19.10M | -14.41M | -19.37M | -50.09M |
Balance Sheet | |||||
| Total Assets | 14.40M | 12.82M | 5.73M | 16.57M | 34.14M |
| Cash, Cash Equivalents and Short-Term Investments | 10.58M | 9.77M | 2.98M | 13.13M | 30.36M |
| Total Debt | 413.50K | 168.00K | 541.00K | 896.00K | 739.00K |
| Total Liabilities | 10.91M | 5.95M | 3.65M | 4.92M | 4.48M |
| Stockholders Equity | 3.49M | 6.88M | 2.08M | 11.64M | 29.66M |
Cash Flow | |||||
| Free Cash Flow | -24.02M | -15.50M | -13.83M | -16.66M | -12.62M |
| Operating Cash Flow | -23.90M | -15.49M | -13.65M | -16.34M | -12.54M |
| Investing Cash Flow | -117.28K | -10.00K | -177.00K | -311.00K | -77.00K |
| Financing Cash Flow | 24.28M | 21.74M | 3.79M | -275.00K | 41.90M |
Ondine Biomedical, Inc. Technical Analysis
Negative
11.75
Price Trends
13.40
Negative
13.55
Negative
11.70
Negative
Market Momentum
-0.58
Positive
34.22
Neutral
11.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBI, the sentiment is Negative. The current price of 11.75 is below the 20-day moving average (MA) of 12.45, below the 50-day MA of 13.40, and above the 200-day MA of 11.70, indicating a bearish trend. The MACD of -0.58 indicates Positive momentum. The RSI at 34.22 is Neutral, neither overbought nor oversold. The STOCH value of 11.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBI.
Ondine Biomedical, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | £1.58B | -10.12 | -35.45% | ― | 14.80% | 16.88% | |
59 Neutral | £24.62M | -52.78 | -5.25% | ― | 95.16% | 85.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £62.98M | -8.87 | -55.47% | ― | ― | 19.83% | |
49 Neutral | £58.32M | -3.29 | -1411.54% | ― | 22.87% | 13.35% | |
47 Neutral | £316.17M | -7.25 | -2929.47% | ― | ― | ― | |
47 Neutral | £73.55M | -4.36 | -116.21% | ― | 81.46% | -15.88% |
* Healthcare Sector Average
GB:OBI
Ondine Biomedical, Inc.
11.25
-4.00
-26.23%
GB:AVCT
Avacta Group plc
67.50
12.50
22.73%
GB:SBTX
SkinBioTherapeutics
9.50
-6.00
-38.71%
GB:4BB
4basebio UK Societas
475.00
-380.00
-44.44%
GB:POLB
Poolbeg Pharma Ltd.
8.25
4.10
98.80%
GB:ONT
Oxford Nanopore Technologies PLC
161.40
-9.60
-5.61%
Ondine Biomedical, Inc. Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Ondine’s Phase 3 Trial Shows 40% Cut in Surgical Site Infections
Positive
Sep 1, 2026
Ondine Biomedical has reported positive topline results from its Phase 3 LANTERN trial, which tested its nasal photodisinfection technology as an add-on to standard care for preventing surgical site infections. The study enrolled 5,188 patients ac...
Business Operations and StrategyProduct-Related Announcements
Ondine’s Steriwave Adopted by Scotland’s Largest Joint Replacement Centre
Positive
Jul 30, 2026
NHS Golden Jubilee, the UK’s largest hip and knee replacement centre and a key provider of elective orthopaedic care in Scotland, has become the first hospital in the country to adopt Ondine Biomedical’s Steriwave nasal photodisinfecti...
Business Operations and StrategyProduct-Related Announcements
Ondine Biomedical Narrows Timeline for Phase 3 LANTERN Trial Results
Positive
Jul 13, 2026
Ondine Biomedical has updated the expected timing for topline results from its LANTERN Phase 3 pivotal study of its nasal photodisinfection therapy to cut surgical site infections, with data now anticipated in about six weeks as final data managem...
Business Operations and StrategyProduct-Related Announcements
Ondine Showcases Steriwave at Photodynamic Forum as Phase 3 Trial Advances
Positive
Jul 1, 2026
Ondine Biomedical, a developer of non-antibiotic, light-activated antimicrobial therapies, is building a portfolio around its Steriwave nasal photodisinfection platform and related photodisinfection products for a range of infection-related indica...
Executive/Board ChangesShareholder Meetings
Ondine Biomedical shareholders back board and auditors at AGM
Positive
Jun 30, 2026
Shareholders of Ondine Biomedical Inc. unanimously backed the re-election of chair Carolyn Cross and president Nicolas G. Loebel at the company’s 30 June Annual General Meeting, with all other director nominees also securing strong support d...
Business Operations and StrategyProduct-Related Announcements
Ondine’s Steriwave Cuts Skull-Base Surgery Infections by 78% in Leeds Study
Positive
Jun 30, 2026
Ondine Biomedical reported that a study from Leeds Teaching Hospitals has been published showing its Steriwave nasal photodisinfection system significantly outperforms standard mupirocin-based care in endoscopic anterior skull-base surgery. The si...
Business Operations and StrategyProduct-Related Announcements
Ondine Nears Top-Line Data from Landmark Phase 3 Study of Nasal Photodisinfection
Positive
Jun 22, 2026
Ondine Biomedical has announced progress in its LANTERN Phase 3 pivotal trial evaluating its non-antibiotic nasal photodisinfection technology for reducing surgical site infections. Endpoint adjudication is complete, principal investigators are fi...
Business Operations and StrategyProduct-Related Announcements
Ondine’s nasal photodisinfection cuts infections in complex brain surgery
Positive
Jun 18, 2026
Ondine Biomedical reported interim results from a 189-patient study at Leeds Teaching Hospitals showing that its Steriwave nasal photodisinfection, applied immediately before complex brain surgery performed through the nose, reduced surgical site ...
Business Operations and StrategyExecutive/Board Changes
Ondine Biomedical Expands Equity Incentives Ahead of Key FDA Milestone
Positive
Jun 8, 2026
Ondine Biomedical has granted 3,121,471 restricted share units to employees and executive directors, with vesting tied to U.S. FDA marketing approval for its nasal photodisinfection therapy, representing about 0.56% of current share capital. The c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.